source
- Pathos AI signs major ADC partnership with Chinese biotech Alphamab and targets up to $300M Series E raisePathos AI, a technology and drug development company, announced a major antibody‑drug conjugate (ADC) collaboration with Chinese biotech Alphamab. The firm also disclosed a partnership with AstraZ…
- FDA expands Pluvicto label, allowing most metastatic prostate cancer patients to receive the therapyThe U.S. Food and Drug Administration has approved an expanded label for Novartis’ radiopharmaceutical Pluvicto, permitting its use together with hormone therapy in metastatic prostate cancer. The…